New normal linear modeling strategies are presented for analyzing read counts from RNA-seq experiments. The voom method estimates the mean-variance relationship of the log-counts, generates a precision weight for each observation and enters these into the limma empirical Bayes analysis pipeline. This opens access for RNA-seq analysts to a large body of methodology developed for microarrays. Simulation studies show that voom performs as well or better than count-based RNA-seq methods even when the data are generated according to the assumptions of the earlier methods. Two case studies illustrate the use of linear modeling and gene set testing methods.

/pdf/voom-precision-weights-unlock-linear-model-analysis-tools-5bgw8lj2b8.pdf

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

Droplet Barcoding for Single-Cell Transcriptomics Applied to Embryonic Stem Cells

Read alignment is an ongoing challenge for the analysis of data from sequencing technologies. This article proposes an elegantly simple multi-seed strategy, called seed-and-vote, for mapping reads to a reference genome. The new strategy chooses the mapped genomic location for the read directly from the seeds. It uses a relatively large number of short seeds (called subreads) extracted from each read and allows all the seeds to vote on the optimal location. When the read length is <160 bp, overlapping subreads are used. More conventional alignment algorithms are then used to fill in detailed mismatch and indel information between the subreads that make up the winning voting block. The strategy is fast because the overall genomic location has already been chosen before the detailed alignment is done. It is sensitive because no individual subread is required to map exactly, nor are individual subreads constrained to map close by other subreads. It is accurate because the final location must be supported by several different subreads. The strategy extends easily to find exon junctions, by locating reads that contain sets of subreads mapping to different exons of the same gene. It scales up efficiently for longer reads.

/pdf/the-subread-aligner-fast-accurate-and-scalable-read-mapping-2r44yfipz6.pdf

The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote

Over the last decade, the introduction of microarray technology has had a profound impact on gene expression research. The publication of studies with dissimilar or altogether contradictory results, obtained using different microarray platforms to analyze identical RNA samples, has raised concerns about the reliability of this technology. The MicroArray Quality Control (MAQC) project was initiated to address these concerns, as well as other performance and data analysis issues. Expression data on four titration pools from two distinct reference RNA samples were generated at multiple test sites using a variety of microarray-based and alternative technology platforms. Here we describe the experimental design and probe mapping efforts behind the MAQC project. We show intraplatform consistency across test sites as well as a high level of interplatform concordance in terms of genes identified as differentially expressed. This study provides a resource that represents an important first step toward establishing a framework for the use of microarrays in clinical and regulatory settings.

/pdf/the-microarray-quality-control-maqc-project-shows-inter-and-284p6wv6is.pdf

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

In multicellular organisms, biological function emerges when heterogeneous cell types form complex organs. Nevertheless, dissection of tissues into mixtures of cellular subpopulations is currently challenging. We introduce an automated massively parallel single-cell RNA sequencing (RNA-seq) approach for analyzing in vivo transcriptional states in thousands of single cells. Combined with unsupervised classification algorithms, this facilitates ab initio cell-type characterization of splenic tissues. Modeling single-cell transcriptional states in dendritic cells and additional hematopoietic cell types uncovers rich cell-type heterogeneity and gene-modules activity in steady state and after pathogen activation. Cellular diversity is thereby approached through inference of variable and dynamic pathway activity rather than a fixed preprogrammed cell-type hierarchy. These data demonstrate single-cell RNA-seq as an effective tool for comprehensive cellular decomposition of complex tissues.

/pdf/massively-parallel-single-cell-rna-seq-for-marker-free-uiiq82x1s8.pdf

Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types

Standard controls and best practice guidelines advance acceptance of data from research, preclinical and clinical laboratories by providing a means for evaluating data quality. The External RNA Controls Consortium (ERCC) is developing commonly agreed-upon and tested controls for use in expression assays, a true industry-wide standard control.

The External RNA Controls Consortium: a progress report.

This is a transcript from a session held at the Biotechnology Industry Organization 2005 Annual International Convention held in Philadelphia from 19th to 22nd June, 2005, where the authors discussed their experiences and answered questions from the floor. All biotechnology companies can benefit from public funding – small, mid-size and large corporations and non-profits. Examples include funding for applied health research; the BioShield homeland security initiative; and sales to federal, state and local government customers. The panel discussed the basics: (1) where to find money (for example, at NIH, FDA, DOD, DHS, DOE, EPA, via ATP, SBIR and DARPA grants, or from philanthropies such as the Gates Foundation); (2) pros and cons of various approaches to obtaining public funds (via earmarked appropriations, grants, cooperative research agreements, procurement contracts or philanthropy); (3) structuring the deal (allocating liability, intellectual property ownership, deliverables, sharing and commercialising results); and (4) managing the relationship (reporting requirements, follow-on funding).

/pdf/winning-the-game-public-funds-for-biotech-companies-5fi13q0236.pdf

Winning the game: Public funds for biotech companies

/pdf/atcc-not-involved-in-negotiations-with-india-s0mslhku18.pdf

Jesus Soriano

Papers

The External RNA Controls Consortium: a progress report.

Winning the game: Public funds for biotech companies

ATCC not involved in negotiations with India.